Overview
The Kallikrein-2 inhibitor (KLK2b) is a highly specialized peptide designed to inhibit the activity of the human glandular kallikrein-2 (KLK2) enzyme. Comprising 12 amino acids, this linear peptide plays an essential role in research related to prostate cancer, where elevated levels of KLK2 in tissues and serum are frequently observed. By inhibiting KLK2, KLK2b serves as a potential therapeutic candidate for prostate cancer treatment, making it a critical reagent for researchers focused on cancer biomarker studies.
Key Features
- Inhibits the KLK2 enzyme, a known biomarker for prostate cancer
- 12 amino acid structure for specific activity
- Supports cancer research initiatives by providing deeper insights into KLK2 function
- Available in a convenient 5mg package
- Compatible with various assay and experimental setups
Specifications
| Name: | Kallikrein-2 inhibitor (KLK2b) |
| Concentration: | 5mg |
| Amino Acid Sequence: | 12 amino acids |
FAQ
What is the primary use of KLK2b?
KLK2b is primarily used as an inhibitor of the KLK2 enzyme, particularly in research related to prostate cancer, where KLK2 acts as a significant biomarker.
How should KLK2b be stored?
For optimal stability, KLK2b should be stored at -20°C. Avoid repeated freeze-thaw cycles to maintain its effectiveness.
Can KLK2b be used in various assays?
Yes, KLK2b is versatile and compatible with a range of assay types, helping researchers explore the role of KLK2 in cancer and other physiological studies.
Explore how KLK2b fits into your research by checking out some of our related products, like the PKG Substrate or Autocamtide-2. Each of these items can complement your work with peptides, including our full selection of peptides designed to deliver precise results. Don’t miss out on the potential of KLK2b for your studies!




Reviews
There are no reviews yet.